JP2024543345A - Mds関連貧血及び他の状態を処置するための化合物 - Google Patents
Mds関連貧血及び他の状態を処置するための化合物 Download PDFInfo
- Publication number
- JP2024543345A JP2024543345A JP2024526836A JP2024526836A JP2024543345A JP 2024543345 A JP2024543345 A JP 2024543345A JP 2024526836 A JP2024526836 A JP 2024526836A JP 2024526836 A JP2024526836 A JP 2024526836A JP 2024543345 A JP2024543345 A JP 2024543345A
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- subject
- compound
- pharma
- mds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280069P | 2021-11-16 | 2021-11-16 | |
| US63/280,069 | 2021-11-16 | ||
| US202263357240P | 2022-06-30 | 2022-06-30 | |
| US63/357,240 | 2022-06-30 | ||
| PCT/US2022/049969 WO2023091414A1 (en) | 2021-11-16 | 2022-11-15 | Compounds for treating mds-associated anemias and other conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543345A true JP2024543345A (ja) | 2024-11-21 |
| JP2024543345A5 JP2024543345A5 (cg-RX-API-DMAC7.html) | 2025-11-26 |
Family
ID=84887868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526836A Withdrawn JP2024543345A (ja) | 2021-11-16 | 2022-11-15 | Mds関連貧血及び他の状態を処置するための化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250108049A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4433057A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024543345A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240107326A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022390088B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236880A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024001431A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312679A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005852A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202329935A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023091414A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024238659A1 (en) * | 2023-05-15 | 2024-11-21 | Agios Pharmaceuticals, Inc. | Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one |
| WO2026076363A1 (en) | 2024-10-04 | 2026-04-09 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120693A1 (es) | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| MX384883B (es) | 2015-06-11 | 2025-03-14 | Agios Pharmaceuticals Inc | Métodos para usar activadores de piruvato cinasa. |
| EP3668513B1 (en) | 2017-08-15 | 2021-11-10 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in treating blood disorders |
| KR102682430B1 (ko) | 2017-11-22 | 2024-07-08 | 아지오스 파마슈티컬스 아이엔씨. | N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태 |
| JP2022533227A (ja) | 2019-05-22 | 2022-07-21 | アジオス ファーマシューティカルズ, インコーポレイテッド | N-(4-(4-(シクロプロピルメチル)ピペラジン-1-カルボニル)フェニル)キノリン-8-スルホンアミドの結晶性塩形態 |
-
2022
- 2022-11-15 KR KR1020247019391A patent/KR20240107326A/ko not_active Withdrawn
- 2022-11-15 MX MX2024005852A patent/MX2024005852A/es unknown
- 2022-11-15 CA CA3236880A patent/CA3236880A1/en active Pending
- 2022-11-15 TW TW111143555A patent/TW202329935A/zh unknown
- 2022-11-15 EP EP22839539.8A patent/EP4433057A1/en active Pending
- 2022-11-15 US US18/711,090 patent/US20250108049A1/en active Pending
- 2022-11-15 WO PCT/US2022/049969 patent/WO2023091414A1/en not_active Ceased
- 2022-11-15 IL IL312679A patent/IL312679A/en unknown
- 2022-11-15 JP JP2024526836A patent/JP2024543345A/ja not_active Withdrawn
- 2022-11-15 AU AU2022390088A patent/AU2022390088B2/en active Active
-
2024
- 2024-05-14 CL CL2024001431A patent/CL2024001431A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022390088B2 (en) | 2026-07-02 |
| WO2023091414A1 (en) | 2023-05-25 |
| AU2022390088A1 (en) | 2024-05-09 |
| KR20240107326A (ko) | 2024-07-09 |
| CA3236880A1 (en) | 2023-05-25 |
| MX2024005852A (es) | 2024-05-28 |
| CL2024001431A1 (es) | 2024-10-25 |
| US20250108049A1 (en) | 2025-04-03 |
| EP4433057A1 (en) | 2024-09-25 |
| IL312679A (en) | 2024-07-01 |
| TW202329935A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6852073B2 (ja) | 悪性病変を処置する方法 | |
| KR102400737B1 (ko) | 치료적으로 활성인 화합물의 약제학적 조성물 | |
| TW202521120A (zh) | 藥物組合物及其應用 | |
| JP2021181478A (ja) | 貧血治療のための組成物及び方法 | |
| AU2016340087B2 (en) | Combination therapy for treating malignancies | |
| TW201601727A (zh) | 治療固態腫瘤之方法 | |
| UA123400C2 (uk) | Комбінована терапія для лікування злоякісних пухлин | |
| TWI866427B (zh) | 雌激素受體降解劑之給藥方案 | |
| US20250108049A1 (en) | Compounds for treating mds-associated anemias and other conditions | |
| JP2024536328A (ja) | Ptpn11阻害剤とkras g12c阻害剤を用いた併用療法 | |
| CN103429239A (zh) | 增加网织红细胞血红蛋白含量的方法 | |
| AU2025271046A1 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| EP4585269A2 (en) | Methods for cancer therapy | |
| KR101741281B1 (ko) | 건선 치료를 위한 a3 아데노신 수용체 작동약 (ib-meca/cf-101)을 포함하는 제약학적 조성물 | |
| JP7493503B2 (ja) | Mcl-1阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物 | |
| EA050684B1 (ru) | Соединения для лечения анемий и других патологических состояний, ассоциированных с mds | |
| WO2025103408A1 (zh) | 治疗alk阳性或ros1阳性的非小细胞肺癌的方法 | |
| TW202440116A (zh) | 組合療法 | |
| CN118382439A (zh) | 用于治疗mds相关贫血和其他病症的化合物 | |
| CN118678960A (zh) | 用于治疗癌症的方法和组合物 | |
| WO2026076363A1 (en) | Compounds for treating mds-associated anemias and other conditions | |
| RU2818453C2 (ru) | Комбинация ингибитора mcl-1 и мидостаурина, ее применения и фармацевтические композиции | |
| TW202404599A (zh) | 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法 | |
| TW202416992A (zh) | 雌激素受體降解劑之給藥方案 | |
| CN121368483A (zh) | 雌激素受体降解剂与cdk4抑制剂的组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250411 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251114 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251114 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20260724 |